← Browse by Condition
Medical Condition
parp inhibitor
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 1, Phase 2
NCT07359066 Phase 1, Phase 2
Recruiting
An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors
Enrollment
210 pts
Location
China
Sponsor
Shanghai SciBrunch Therapeutic...
NCT06197581
Recruiting
Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
Enrollment
148 pts
Location
China
Sponsor
Cancer Institute and Hospital,...